Dr. Turner added that while manufacturing and regulatory requirements are more sophisticated in the device and OTC drug categories, gross margins are much greater in these areas and better enable the Company to leverage its core manufacturing competencies.
Commenting on DelSite, Dr. Turner noted increasing interest being shown by commercial companies and government health agencies in the drug delivery subsidiary's nasal and injectible formulation technologies. Subsequent to the quarter's end, DelSite received test supplies of a government-approved H5N1 bird flu antigen and is now preparing to initiate toxicology studies for a nasally administered vaccine. If successful, a human safety trial will start by year-end.
Other activities that evidence the continuing successful development of DelSite's drug and vaccine delivery technologies include a CRADA with the National Cancer Institute (NCI) for testing GelVac(TM) nasal powder formulation for a nasal Human Papillomavirus (HPV) vaccine.
Additional DelSite achievements during the current year have included
pre-licensing and evaluation agreements with a number of companies,
including Nastech Pharmaceuticals for intranasal delivery of peptide and
protein therapeutics; the International Vaccine Institute (IVI) for
sublingual delivery of new and existing vaccines to be used in immunization
programs in needy areas of the developing world; AriaVax, Inc. for
development of an investigational vaccine against HIV infection;
EndoBiologics, Inc. for development of a vaccine against bacill
|SOURCE Carrington Laboratories, Inc.|
Copyright©2007 PR Newswire.